Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with <scp>AZD4017</scp> in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase <scp>II</scp> study-Reference-Cited by-同舟云学术

Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study

Published:2022-01-25 Issue:5 Volume:24 Page:881-890
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Yadav Yogesh¹,Dunagan Kelly²,Khot Rachita³,Venkatesh Sudhakar K.²,Port John²,Galderisi Alfonso⁴,Cobelli Claudio⁴,Wegner Craig⁵,Basu Ananda¹^ORCID,Carter Rickey⁶,Basu Rita¹^ORCID

Affiliation:

1. Division of Endocrinology University of Virginia Charlottesville Virginia USA

2. Department of Radiology Mayo Clinic Rochester Minnesota USA

3. Division of Body Imaging, Department of Radiology and Medical Imaging University of Virginia Charlottesville Virginia USA

4. Department of Woman and Child's health University of Padova Padova Veneto Italy

5. Retired from Emerging & Open Innovations Unit, IMED Biotech Unit AstraZeneca USA

6. Department of Quantitative Health Sciences Mayo Clinic Jacksonville Florida USA

Funder

AstraZeneca Pharma Poland

National Center for Advancing Translational Sciences

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14646

Reference42 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

3. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

4. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

5. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, 11b-0048, effectively suppresses the expression of 11β-HSD1 activated in cultured keratinocytes and in diabetic murine skin;2024-01-12

2. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance;Journal of Hepatology;2023-12

3. Editorial: Liver hypercortisolism as a potential target for MASH treatment;Alimentary Pharmacology & Therapeutics;2023-11-20

4. 11β‐Hydroxysteroid dehydrogenase and the brain: Not (yet) lost in translation;Journal of Internal Medicine;2023-11-08

5. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial;Nature Communications;2023-10-12